Navigation Links
Convergence Pharmaceuticals Announces Start of Phase II Study for Cav2.2 Selective Blocker, CNV2197944 in Pain Associated with Post-Herpetic Neuralgia
Date:4/23/2013

CAMBRIDGE, England, April 23, 2013 /PRNewswire/ --

Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, today announces that it has started a Phase II proof of concept study with CNV2197944 in pain associated with post-herpetic neuralgia (PHN). Convergence is conducting the development of CNV2197944 on behalf of Calchan Ltd.

The trial is a randomised double-blind, placebo controlled, phase II study to evaluate the efficacy and safety of orally administered CNV2197944 in patients with PHN. The primary endpoint of the trial is the effect of repeat oral dosing of CNV2197944 on the pain experienced in PHN, as measured by the Pain Intensity Numeric Rating Scale (PI-NRS), after three weeks, compared to baseline. The study is expected to conclude in 1Q2014.

Post-herpetic neuralgia (PHN) is a nerve pain due to damage caused by the varicella zoster virus (Shingles or Chicken Pox). Typically, the neuralgia is confined to a dermatomic area of the skin and follows an outbreak of the virus in the same dermatomic area. Injury to sensory nerves can cause excruciating pain, sometimes persisting for months or years.

CNV2197944 is a novel, small molecule, state-dependent calcium channel blocker, designed to selectively inhibit highly active Cav2.2 channels. Based on positive pre-clinical and clinical data already reported, it is believed that CNV2197944 will be an effective treatment for neuropathic pain with analgesic potential for a broad range of chronic pain conditions. Extensive safety and toxicology studies to support the clinical development of CNV2197944 have also been completed, which suggest an excellent margin of safety and tolerability. CNV2197944 is the only truly selective Cav2.2 blocker in clinical development and has the potential to be a first in class treatment for chronic pain.

'/>"/>

SOURCE Convergence Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Convergence Pharmaceuticals Announces Successful Interim Data from Ground-Breaking Phase II Trigeminal Neuralgia Study
2. Eighth Annual WLSA Convergence Summit Focuses on Moving from Innovation to Adoption
3. ISIS Pharmaceuticals Initiates a Clinical Study of ISIS-SMN Rx in Infants With Spinal Muscular Atrophy
4. Immune Pharmaceuticals CEO to Chair BIO International Panel "Can Israel Become the Next Biotech Startup Nation?"
5. European Nuclear Medicine / Radiopharmaceuticals Market - Global Trends & Forecasts to 2017
6. Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance In The United States For Its Previously Announced Acquisition Of Obagi Medical Products, Inc.
7. Statement from the Cystic Fibrosis Foundation on Promising Phase 2 Clinical Trial Results of Kalydeco and VX-661 (Vertex Pharmaceuticals Inc.)
8. ADial Pharmaceuticals Announces Agreement With FDA For Phase III Trial Of AD04 For Alcohol Use Disorder In Patients Of Targeted Genotypes
9. Inovio Pharmaceuticals Universal H1N1 Influenza Vaccine Achieves Protective Immune Responses Comparable to Conventional Vaccine in Phase I Study
10. Savara Pharmaceuticals Initiates Phase 2 Clinical Trial of AeroVanc for MRSA Lung Infection in Cystic Fibrosis Patients
11. Vanda Pharmaceuticals to Announce First Quarter 2013 Financial Results on May 9, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... ANGELES , July 11, 2014 /PRNewswire-iReach/ -- ... e-liquid, a vegetable-glycol solution for use in portable ... of the active ingredients in cannabis, cannabidiol offers ... personal vaporizer devices, and other vaporizer technology. ... Cannabis naturally contains 483 different compounds which ...
(Date:7/11/2014)... , July 11, 2014 Patient engagement ... and, consequently, organizations are turning to an assortment ... As part of this evolving approach to ... educate, communicate and engage patients throughout their experiences ... patient empowerment. By mapping the patient journey and ...
(Date:7/11/2014)... N.C. , July 11, 2014 ... approaches are evolving across industry sectors to better ... examining better ways to engage with and understand ... inform themselves and make critical purchasing decisions. ... firm, Best Practices, LLC, one area where organizations ...
Breaking Medicine Technology:VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2New Technologies Transforming Consumer Marketing Research Playbook 2
... HORSHAM, Pa., Feb. 23, 2011 Centocor Ortho Biotech ... of Appeals for the Federal Circuit in Washington, D.C. ... the company $1.8 billion after finding Abbott Laboratories liable ... court ruled that the patent relating to Centocor anti-tumor ...
... 2011 Xenogenics Corporation ("Xenogenics"), a majority owned subsidiary ... pleased to announce it has retained the Emmes Group ... capital formation strategy to help finance expanded human clinical ... animal testing and initial human use, the Ideal BioStent™ ...
Cached Medicine Technology:Court of Appeals Overturns $1.8 Billion Patent Verdict for Centocor Ortho Biotech Inc. 2Xenogenics Corporation Retains the Emmes Group to Advise on Fund Raising Efforts 2Xenogenics Corporation Retains the Emmes Group to Advise on Fund Raising Efforts 3Xenogenics Corporation Retains the Emmes Group to Advise on Fund Raising Efforts 4
(Date:7/12/2014)... PA (PRWEB) July 12, 2014 Doylestown ... covering a variety of men’s health questions. Paddock ... specific to men, why women live longer than men, ... Men's Health Made Simple featured on Doylestown ... get a hernia at any age. If you notice ...
(Date:7/12/2014)... Dubai is buzzing with the announcement ... to the UAE. The National Basketball Association’s (NBA) ... the UAE from 28-31 October to lead the Kareem ... awareness. The event is being organized by Maven Marketing ... company based in Dubai. The announcement was made today ...
(Date:7/12/2014)... 12, 2014 Wright & Schulte LLC, an ... Just For Men Lawsuits (case #59776/2014), announces they have ... reports that allege the popular hair dye, Just For Men, ... their face, neck and other areas. In addition to detailing ... chemical burns , the advertisements being run by Wright & ...
(Date:7/12/2014)... Palm Beach, FL (PRWEB) July 12, 2014 ... variety of high-quality peptides that are used solely in ... To honor two successful years in business, Maxim Peptide, ... LLC, has just launched a new and updated website ... the research blog section has been updated with fascinating ...
(Date:7/11/2014)... July 12, 2014 Recently, MagicQuinceaneraDresses.com, the ... its new collection of 2014 Quinceanera dresses . ... who want to look fashionable without paying a large ... prices, up to 57% off. , The company’s online ... to get amazing special occasion outfits. In addition to ...
Breaking Medicine News(10 mins):Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2Health News:Los Angeles Basketball Legend Headed to Dubai 2Health News:Los Angeles Basketball Legend Headed to Dubai 3Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 2Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 3Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 4Health News:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Health News:Cheap Quinceanera Dresses Now Available At MagicQuinceaneraDresses.com 2
... led by researchers from North Carolina State University ... properties into microneedles vanishingly thin needles that ... devices. Researchers expect the findings to spur development ... cause less pain, tissue damage and skin inflammation ...
... ... childhood crippler spinal muscular atrophy (SMA), is awarding a $250,000 research grant to Dr. ... Ohio State University. , ... (PRWEB) May 19, 2010 -- Richmond, Virginia-based FightSMA, a nonprofit dedicated to developing ...
... of conventional seed , TUESDAY, May 18 (HealthDay News) -- ... but a new British study finds that wild birds beg ... conventional wheat seed, which helps them pack in the protein. ... said in a news release from the school, were likely ...
... it,s committed to responsible online advertising , WEDNESDAY, May ... the latest new media technologies -- including cell phones, ... expanding digital universe -- to reach young drinkers, a ... be keeping up with the marketing trend, the report,s ...
... ... Experience, View Their Photos, and Learn What Footwear To Pack for an African Safari , ... Seattle, Wash. (PRWEB) May 17, 2010 -- Good ... online shoe retailer before embarking on her honeymoon, vowing to pack only five pairs of shoes ...
... The ... xSCC Skin, and xMM skin, respectively on Basal Cell Cancer, Squamous Cell Cancer, and Malignant ... that not only tracks and stores images of the skin, but also allows for recording ... ...
Cached Medicine News:Health News:New microneedle antimicrobial techniques may foster medical tech innovation 2Health News:FightSMA Awards $250,000 Grant to Gene Researcher at The Ohio State University 2Health News:Wild Birds Shun Organic Food 2Health News:Alcohol Companies Use New Media to Lure Young Drinkers: Report 2Health News:Alcohol Companies Use New Media to Lure Young Drinkers: Report 3Health News:Alcohol Companies Use New Media to Lure Young Drinkers: Report 4Health News:The Bachelor's Molly Malaney Blogs About Honeymoon at Onlineshoes.com 2Health News:The Bachelor's Molly Malaney Blogs About Honeymoon at Onlineshoes.com 3Health News:neXante Turns Apple's iPhone Into Skin Cancer Surveillance Support Tool And Health Record 2
Ovulation test for the rapid detection of LH in urine. Our ovulation tests, designed to accurately detect fertility in a user-friendly presentation, are also available for professional and over-the-c...
... Clinitek® 50 analyzer is ... physician offices and smaller ... consistency of state-of-the-art instrument-based ... more efficient way to ...
... The HemoPoint H2 Hemoglobin Measurement System ... of hemoglobin in arterial, venous, or ... and children in a professional point-of-care ... 3010-100 is indicated for use in ...
... Self-Sampling: ,Place the ImmunoDip into ... precise amount of sample needed for,an accurate ... run to completion,in 3 minutes. , ... color bands remain stable,for at least eight ...
Medicine Products: